[1] |
HOOS A. Development of immuno-oncology drugs—from CTLA4 to PD1 to the next generations[J]. Nat Rev Drug Discov, 2016, 15(4): 235-247. DOI: 10.1038/nrd.2015.35.
|
[2] |
POSTOW MA, SIDLOW R, HELLMANN MD. Immune-related adverse events associated with immune checkpoint blockade[J]. N Engl J Med, 2018, 378(2): 158-168. DOI: 10.1056/NEJMra1703481.
|
[3] |
PAUKEN KE, DOUGAN M, ROSE NR, et al. Adverse events following cancer immunotherapy: Obstacles and opportunities[J]. Trends Immunol, 2019, 40(6): 511-523. DOI: 10.1016/j.it.2019.04.002.
|
[4] |
RAMOS-CASALS M, BRAHMER JR, CALLAHAN MK, et al. Immune-related adverse events of checkpoint inhibitors[J]. Nat Rev Dis Primers, 2020, 6(1): 38. DOI: 10.1038/s41572-020-0160-6.
|
[5] |
XU C, CHEN YP, DU XJ, et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis[J]. BMJ, 2018, 363: k4226. DOI: 10.1136/bmj.k4226.
|
[6] |
YOEST JM. Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: A short review[J]. Immunotargets Ther, 2017, 6: 73-82. DOI: 10.2147/ITT.S126227.
|
[7] |
PARAKH S, CEBON J, KLEIN O. Delayed autoimmune toxicity occurring several months after cessation of anti-PD-1 therapy[J]. Oncologist, 2018, 23(7): 849-851. DOI: 10.1634/theoncologist.2017-0531.
|
[8] |
SANDIGURSKY S, MOR A. Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors[J]. Curr Rheumatol Rep, 2018, 20(10): 65. DOI: 10.1007/s11926-018-0770-0.
|
[9] |
KHOJA L, DAY D, WEI-WU CHEN T, et al. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: A systematic review[J]. Ann Oncol, 2017, 28(10): 2377-2385. DOI: 10.1093/annonc/mdx286.
|
[10] |
LANGER CJ, GADGEEL SM, BORGHAEI H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: A randomised, phase 2 cohort of the open-label KEYNOTE-021 study[J]. Lancet Oncol, 2016, 17(11): 1497-1508. DOI: 10.1016/S1470-2045(16)30498-3.
|
[11] |
SCHMID P, ADAMS S, RUGO HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer[J]. N Engl J Med, 2018, 379(22): 2108-2121. DOI: 10.1056/NEJMoa1809615.
|
[12] |
WOLCHOK JD, CHIARION-SILENI V, GONZALEZ R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma[J]. N Engl J Med, 2017, 377(14): 1345-1356. DOI: 10.1056/NEJMoa1709684.
|
[13] |
ABDEL-WAHAB N, SHAH M, LOPEZ-OLIVO MA, et al. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: A systematic review[J]. Ann Intern Med, 2018, 168(2): 121-130. DOI: 10.7326/M17-2073.
|
[14] |
KOSTINE M, FINCKH A, BINGHAM CO, et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors[J]. Ann Rheum Dis, 2021, 80(1): 36-48. DOI: 10.1136/annrheumdis-2020-217139.
|
[15] |
LEE PC, CHAO Y, CHEN MH, et al. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma[J]. J Immunother Cancer, 2020, 8(2): e001072. DOI: 10.1136/jitc-2020-001072.
|
[16] |
Editor-in-chief of the Guidelines Working Committee of the Chinese Society of Clinical Oncology. Guidelines for the management of toxicity related to immune checkpoint inhibitors[M]. Beijing: People's Health Publishing House, 2021: 53.中国临床肿瘤学会指南工作委员会主编. 免疫检查点抑制剂相关的毒性管理指南[M]. 北京: 人民卫生出版社, 2021: 53.
|
[17] |
SHI GM, HUANG XY, RENG ZG, et al. Chinese expert consensus on the management of immune-related adverse events of hepato-cellular carcinoma treated with immune checkpoint inhibitors (2021 edition) [J]. Chin J Dig Surg, 2021, 20(12): 1241-1258. DOI: 10.3760/cma.j.cn115610-20211125-00594.施国明, 黄晓勇, 任正刚, 等. 肝癌免疫检查点抑制剂相关不良反应管理中国专家共识(2021版)[J]. 中华消化外科杂志, 2021, 20(12): 1241-1258. DOI: 10.3760/cma.j.cn115610-20211125-00594.
|
[18] |
SIBAUD V. Dermatologic reactions to immune checkpoint inhibitors: Skin toxicities and immunotherapy[J]. Am J Clin Dermatol, 2018, 19(3): 345-361. DOI: 10.1007/s40257-017-0336-3.
|
[19] |
SOSA A, LOPEZ CADENA E, SIMON OLIVE C, et al. Clinical assessment of immune-related adverse events[J]. Ther Adv Med Oncol, 2018, 10: 1758835918764628. DOI: 10.1177/1758835918764628.
|
[20] |
PUZANOV I, DIAB A, ABDALLAH K, et al. Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group[J]. J Immunother Cancer, 2017, 5(1): 95. DOI: 10.1186/s40425-017-0300-z.
|
[21] |
THOMPSON JA, SCHNEIDER BJ, BRAHMER J, et al. Management of immunotherapy-related toxicities, version 1.2019[J]. J Natl Compr Canc Netw, 2019, 17(3): 255-289. DOI: 10.6004/jnccn.2019.0013.
|
[22] |
BRAHMER JR, LACCHETTI C, SCHNEIDER BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline[J]. J Clin Oncol, 2018, 36(17): 1714-1768. DOI: 10.1200/JCO.2017.77.6385.
|
[23] |
BARROSO-SOUSA R, BARRY WT, GARRIDO-CASTRO AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: A systematic review and meta-analysis[J]. JAMA Oncol, 2018, 4(2): 173-182. DOI: 10.1001/jamaoncol.2017.3064.
|
[24] |
DELIVANIS DA, GUSTAFSON MP, BORNSCHLEGL S, et al. Pembrolizumab-Induced Thyroiditis: Comprehensive clinical review and insights into underlying involved mechanisms[J]. J Clin Endocrinol Metab, 2017, 102(8): 2770-2780. DOI: 10.1210/jc.2017-00448.
|
[25] |
LU J, LI L, LAN Y, et al. Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction: A systematic review and meta-analysis[J]. Cancer Med, 2019, 8(18): 7503-7515. DOI: 10.1002/cam4.2661.
|
[26] |
GEUKES FOPPEN MH, ROZEMAN EA, van WILPE S, et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management[J]. ESMO Open, 2018, 3(1): e000278. DOI: 10.1136/esmoopen-2017-000278.
|
[27] |
ABU-SBEIH H, ALI FS, LUO W, et al. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis[J]. J Immunother Cancer, 2018, 6(1): 95. DOI: 10.1186/s40425-018-0411-1.
|
[28] |
VERSCHUREN EC, van den EERTWEGH AJ, WONDERS J, et al. Clinical, endoscopic, and histologic characteristics of ipilimumab-associated colitis[J]. Clin Gastroenterol Hepatol, 2016, 14(6): 836-842. DOI: 10.1016/j.cgh.2015.12.028.
|
[29] |
KLEINER DE, BERMAN D. Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma[J]. Dig Dis Sci, 2012, 57(8): 2233-2240. DOI: 10.1007/s10620-012-2140-5.
|
[30] |
VITALE G, LAMBERTI G, COMITO F, et al. Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: From clinical pivotal studies to real-life experience[J]. Expert Opin Biol Ther, 2020, 20(9): 1047-1059. DOI: 10.1080/14712598.2020.1762562.
|
[31] |
NAIDOO J, WANG X, WOO KM, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy[J]. J Clin Oncol, 2017, 35(7): 709-717. DOI: 10.1200/JCO.2016.68.2005.
|
[32] |
WANG H, ZHAO Y, ZHANG X, et al. Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis: A single-institution retrospective study[J]. Cancer Med, 2021, 10(1): 188-198. DOI: 10.1002/cam4.3600.
|
[33] |
MAHMOOD SS, FRADLEY MG, COHEN JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors[J]. J Am Coll Cardiol, 2018, 71(16): 1755-1764. DOI: 10.1016/j.jacc.2018.02.037.
|
[34] |
DELANOY N, MICHOT JM, COMONT T, et al. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study[J]. Lancet Haematol, 2019, 6(1): e48-e48, e57. DOI: 10.1016/S2352-3026(18)30175-3.
|
[35] |
PERRINJAQUET C, DESBAILLETS N, HOTTINGER AF. Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy[J]. Curr Opin Neurol, 2019, 32(3): 500-510. DOI: 10.1097/WCO.0000000000000686.
|
[36] |
CUZZUBBO S, JAVERI F, TISSIER M, et al. Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature[J]. Eur J Cancer, 2017, 73: 1-8. DOI: 10.1016/j.ejca.2016.12.001.
|
[37] |
WANCHOO R, KARAM S, UPPAL NN, et al. Adverse renal effects of immune checkpoint inhibitors: A narrative review[J]. Am J Nephrol, 2017, 45(2): 160-169. DOI: 10.1159/000455014.
|
[38] |
RICHTER MD, CROWSON C, KOTTSCHADE LA, et al. Rheumatic syndromes associated with immune checkpoint inhibitors: A single-center cohort of sixty-one patients[J]. Arthritis Rheumatol, 2019, 71(3): 468-475. DOI: 10.1002/art.40745.
|
[39] |
TOUAT M, MAISONOBE T, KNAUSS S, et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer[J]. Neurology, 2018, 91(10): e985-e994. DOI: 10.1212/WNL.0000000000006124.
|
[40] |
ESFAHANI K, ELKRIEF A, CALABRESE C, et al. Moving towards personalized treatments of immune-related adverse events[J]. Nat Rev Clin Oncol, 2020, 17(8): 504-515. DOI: 10.1038/s41571-020-0352-8.
|
[41] |
SCHWAB I, NIMMERJAHN F. Intravenous immunoglobulin therapy: How does IgG modulate the immune system?[J]. Nat Rev Immunol, 2013, 13(3): 176-189. DOI: 10.1038/nri3401.
|
[42] |
TOUAT M, TALMASOV D, RICARD D, et al. Neurological toxicities associated with immune-checkpoint inhibitors[J]. Curr Opin Neurol, 2017, 30(6): 659-668. DOI: 10.1097/WCO.0000000000000503.
|
[43] |
BADDLEY JW, CANTINI F, GOLETTI D, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents) [J]. Clin Microbiol Infect, 2018, 24(Suppl 2): S10-S20. DOI: 10.1016/j.cmi.2017.12.025.
|
[44] |
BERGQVIST V, HERTERVIG E, GEDEON P, et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis[J]. Cancer Immunol Immunother, 2017, 66(5): 581-592. DOI: 10.1007/s00262-017-1962-6.
|
[45] |
STROUD CR, HEGDE A, CHERRY C, et al. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade[J]. J Oncol Pharm Pract, 2019, 25(3): 551-557. DOI: 10.1177/1078155217745144.
|
[46] |
FRANKLIN C, ROOMS I, FIEDLER M, et al. Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis[J]. Eur J Cancer, 2017, 86: 248-256. DOI: 10.1016/j.ejca.2017.09.019.
|
[47] |
KUO JR, DAVIS AD, RODRIGUEZ EA, et al. Severe diarrhea in the setting of immune checkpoint inhibitors[J]. Case Rep Gastroenterol, 2018, 12(3): 704-708. DOI: 10.1159/000493183.
|
[48] |
PICCHI H, MATEUS C, CHOUAID C, et al. Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment[J]. Clin Microbiol Infect, 2018, 24(3): 216-218. DOI: 10.1016/j.cmi.2017.12.003.
|